Abstract
Diabetic nephropathy is a major cause of end-stage renal failure (ESRF) in patients with both type 1 and type 2 diabetes. Many factors such as genetic and non-genetic promoters, hypertension, hyperglycemia, accumulation of advanced glycation end products (AGEs), dyslipidemia, albuminuria and proteinuria influence the progression of this desease. It is important to determine pathogenesis and treatment of this disease. However, it is difficult to investigate since human diabetes is a heterogeneous and multifactorial disease. Therefore, most of these mechanisms have been investigated in animal experiments. KK/Ta mice have a clearly different genetic background in terms of body weight, blood glucose, impaired glucose tolerance (IGT), urinary albumin excretion and serum triglyceride than BALB/c mice. Renal lesions of KK/Ta mice closely resemble those in human early diabetic nephropathy. Thus, the KK/Ta mouse may serve as a suitable model for the study of type 2 diabetes and early diabetic nephropathy in humans. We reviewed genetic susceptibility using genome-wide linkage analysis and differential display polymerase chain reaction (DD-PCR) or Northern blot analysis, and treatment of diabetic nephropathy using angiotensin type 1 (AT1) receptor blockers (ARB) or thiazolidinediones (TZDs) in KK/Ta mice.
Keywords: kk/ta mouse, diabetic nephropathy, gene, angiotensin type 1 receptor blockers (arb), thiazolidinediones (tzds)
Current Diabetes Reviews
Title: Pathogenesis and Treatment of Type 2 Diabetic Nephropathy: Lessons from the Spontaneous KK/Ta Mouse Model
Volume: 1 Issue: 3
Author(s): Yasuhiko Tomino, Mitsuo Tanimoto, Toshihide Shike, Kenji Shiina, Qiuling Fan, Jie Liao, Tomohito Gohda, Yuichiro Makita and Kazuhiko Funabiki
Affiliation:
Keywords: kk/ta mouse, diabetic nephropathy, gene, angiotensin type 1 receptor blockers (arb), thiazolidinediones (tzds)
Abstract: Diabetic nephropathy is a major cause of end-stage renal failure (ESRF) in patients with both type 1 and type 2 diabetes. Many factors such as genetic and non-genetic promoters, hypertension, hyperglycemia, accumulation of advanced glycation end products (AGEs), dyslipidemia, albuminuria and proteinuria influence the progression of this desease. It is important to determine pathogenesis and treatment of this disease. However, it is difficult to investigate since human diabetes is a heterogeneous and multifactorial disease. Therefore, most of these mechanisms have been investigated in animal experiments. KK/Ta mice have a clearly different genetic background in terms of body weight, blood glucose, impaired glucose tolerance (IGT), urinary albumin excretion and serum triglyceride than BALB/c mice. Renal lesions of KK/Ta mice closely resemble those in human early diabetic nephropathy. Thus, the KK/Ta mouse may serve as a suitable model for the study of type 2 diabetes and early diabetic nephropathy in humans. We reviewed genetic susceptibility using genome-wide linkage analysis and differential display polymerase chain reaction (DD-PCR) or Northern blot analysis, and treatment of diabetic nephropathy using angiotensin type 1 (AT1) receptor blockers (ARB) or thiazolidinediones (TZDs) in KK/Ta mice.
Export Options
About this article
Cite this article as:
Tomino Yasuhiko, Tanimoto Mitsuo, Shike Toshihide, Shiina Kenji, Fan Qiuling, Liao Jie, Gohda Tomohito, Makita Yuichiro and Funabiki Kazuhiko, Pathogenesis and Treatment of Type 2 Diabetic Nephropathy: Lessons from the Spontaneous KK/Ta Mouse Model, Current Diabetes Reviews 2005; 1 (3) . https://dx.doi.org/10.2174/157339905774574374
DOI https://dx.doi.org/10.2174/157339905774574374 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microalbuminuria In Primary Hypertension
Current Hypertension Reviews Editorial [Hot Topic: Current Hypertension Reviews: Hot Topics Hypertension and Diabetes: An Emphasis on the RAS (Guest Editors: Karin A.M. Jandeleit-Dahm and Terri J. Allen)]
Current Hypertension Reviews Impact of Oral 1,25-Dihydroxy Vitamin D (Calcitriol) Replacement Therapy on Coronary Artery Risk Factors in Type 2 Diabetic Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Effects of Estrogens on Atherogenesis
Current Vascular Pharmacology Molecular Markers of Cardiovascular Damage in Hypertension
Current Pharmaceutical Design Simultaneous Assessment of MicroRNAs 126 and 192 in Diabetic Nephropathy Patients and the Relation of these MicroRNAs with Urinary Albumin
Current Molecular Medicine Clinical Significance of the New Cardiovascular Risk Markers in Diabetes Mellitus
Current Diabetes Reviews Chronic Exposure to Low-Level Cadmium in Diabetes: Role of Oxidative Stress and Comparison with Polychlorinated Biphenyls
Current Drug Targets Nutraceuticals and Diet-based Phytochemicals in Type 2 Diabetes Mellitus: From Whole Food to Components with Defined Roles and Mechanisms
Current Diabetes Reviews Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes
Current Pharmaceutical Biotechnology Aldose Reductase, Oxidative Stress and Diabetic Cardiovascular Complications
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of the Osteoprotegerin/RANKL/RANK System in Diabetic Vascular Disease
Current Medicinal Chemistry Antioxidant and Anti-inflammatory Properties of Yttrium Oxide Nanoparticles: New Insights into Alleviating Diabetes
Current Diabetes Reviews The Glomerular Podocyte as a Target of Growth Hormone Action: Implications for the Pathogenesis of Diabetic Nephropathy
Current Diabetes Reviews Distinct Biomarkers for Early Diagnosis of Diabetic Nephropathy
Current Diabetes Reviews Understanding eNOS for Pharmacological Modulation of Endothelial Function: A Translational View
Current Pharmaceutical Design Development of Peptide and Protein Based Radiopharmaceuticals
Current Pharmaceutical Design Proposed Mechanism of <i>Tecoma stans</i> in Diabetes-Associated Complications
The Natural Products Journal Leptin: A Promising Therapeutic Target with Pleiotropic Action Besides Body Weight Regulation
Current Drug Targets Protective Effects of Incretin Against Age-Related Diseases
Current Drug Delivery